Azeria Therapeutics Announces £32.0 Million Series B Financing
Azeria Therapeutics, a newly formed pioneer factor drug discovery company, announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund. Azeria was originally founded in 2017 by Sixth Element
Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology
A company developing a means to edit RNA has raised more than $30 million in a venture capital funding round. Seattle-based Shape Therapeutics, or ShapeTx, said that it had raised a $35.5 million Series A financing, led by New Enterprise Associates
ADC Therapeutics enters licence option deal with Avacta Group
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates. Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind